Trelleborg A.B. plans to strengthen its position in the life sciences market and develop a strong platform in the sector by acquiring Speciality Silicone Fabricators, a manufacturer of high-precision medical silicone products.

"The acquisition is expected to be completed by the second quarter of 2016."

The acquisition is expected to be completed by the second quarter of 2016.

Polpharma S.A., a manufacturer of drug products and active pharmaceutical ingredients (API), has announced its acquirement of biopharmaceutical company EPIRUS Biopharmaceuticals.

Pursuant to the agreement, Polpharma will acquire EPIRUS Netherlands’ proprietary CHOBC cell line platform, a fully-equipped laboratory and bioreactor capabilities for the development of monoclonal antibodies and protein therapeutics, while EPIRUS Biopharma will retain exclusive rights to develop BOW080 and BOW070 for the treatment of ultra-rare blood disorder and uncommon lymphoproliferative disorder respectively.

The acquisition will enable Polpharma to expand its portfolio and EPIRUS Biopharma to pursue its reconstructing efforts of creating a separate company focused on rare disease biological products.

Image: Polpharma S.A.has announced its acquirement of EPIRUS Biopharmaceuticals. Photo: Courtesy of polpharmacommons.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.